Boehringer In­gel­heim ax­es 725 jobs in U.S. re­or­ga­ni­za­tion

Boehringer In­gel­heim is ax­ing 725 po­si­tions in the U.S. as part of a broad re­struc­tur­ing of the com­pa­ny.

In a state­ment sent to End­points, the phar­ma com­pa­ny not­ed that some of the staffers af­fect­ed could wind up in oth­er jobs at Boehringer. A spokesper­son did not pro­vide a break­down on what kind of jobs — ad­min­is­tra­tive, sales or R&D — are in­volved in the cuts.

Fol­low­ing a care­ful ex­am­i­na­tion of our hu­man phar­ma­ceu­ti­cals busi­ness, we made the dif­fi­cult de­ci­sion to elim­i­nate ap­prox­i­mate­ly 725 po­si­tions in the U.S., in­clud­ing ap­prox­i­mate­ly 50 in the state of Con­necti­cut,” the com­pa­ny stat­ed. “Many of the peo­ple im­pact­ed will con­tin­ue to have the op­por­tu­ni­ty to pur­sue new roles with­in the Com­pa­ny.  The ac­tions we are tak­ing now will help us rein­vent the way we serve the needs of our pa­tients, and en­able us to con­tin­ue to make sig­nif­i­cant in­vest­ments in Re­search and De­vel­op­ment to con­tin­ue to iden­ti­fy new med­ical break­throughs.  We are sym­pa­thet­ic to the im­pact this de­ci­sion may have on Boehringer In­gel­heim em­ploy­ees and their fam­i­lies.  We are com­mit­ted to treat­ing all em­ploy­ees with dig­ni­ty, re­spect and sen­si­tiv­i­ty. We will sup­port af­fect­ed em­ploy­ees in a num­ber of ways, in­clud­ing sev­er­ance, out­place­ment ser­vices, and iden­ti­fy­ing oth­er em­ploy­ment op­por­tu­ni­ties with­in the Boehringer In­gel­heim net­work, as ap­pro­pri­ate.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER